Research Summary

Dengue vaccines are immunizations developed to protect against dengue fever, a viral disease transmitted through the bites of infected mosquitoes, primarily Aedes aegypti and Aedes albopictus. The vaccines are designed to stimulate the immune system to produce antibodies against the dengue virus, preventing or reducing the severity of the infection if a vaccinated person is exposed to the virus. Several dengue vaccines have been developed, including the CYD-TDV vaccine (Dengvaxia), which has been approved for use in some countries. Dengue vaccines are particularly important in regions where dengue is endemic and poses a significant public health threat. However, developing an effective dengue vaccine has been challenging due to the existence of multiple dengue virus serotypes, which require the vaccine to provide protection against all four serotypes. Continued research and efforts are focused on improving dengue vaccines to enhance their safety and efficacy, contributing to global efforts to control and prevent the spread of dengue fever.

According to DIResearch's in-depth investigation and research, the global Dengue Vaccines market size will reach US$ XX Million in 2024, and is expected to reach US$ XX Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be US$ XX Million, accounting for approximately XX% of the world. It is expected to reach US$ XX Million in 2030, and the global share will reach XX%.

The major global manufacturers of Dengue Vaccines include Sanofi, Takeda etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.

This report studies the market size, price trends and future development prospects of Dengue Vaccines. Focus on analysing the market share, product portfolio, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Dengue Vaccines market. The report data covers historical data from 2019 to 2023, base year in 2024 and forecast data from 2025 to 2030.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Dengue Vaccines market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Dengue Vaccines industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Dengue Vaccines Include:

Sanofi

Takeda

Dengue Vaccines Product Segment Include:

Dengvaxia

TAK-003

Others

Dengue Vaccines Product Application Include:

Preventive Vaccination in Endemic Regions

Protection for Travelers

Integration into Routine Immunization Programs

Occupational Vaccination

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Dengue Vaccines Industry PESTEL Analysis

Chapter 3: Global Dengue Vaccines Industry Porter's Five Forces Analysis

Chapter 4: Global Dengue Vaccines Major Regional Market Size and Forecast Analysis

Chapter 5: Global Dengue Vaccines Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Dengue Vaccines Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Dengue Vaccines Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Dengue Vaccines Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Dengue Vaccines Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Dengue Vaccines Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Dengue Vaccines Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Dengue Vaccines Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources